← Back to headlines
Regeneron Anticipates $127 Million Q2 Pre-Tax IPR&D Charge
Regeneron Pharmaceuticals expects to incur a pre-tax in-process research and development (IPR&D) charge of approximately $127 million in the second quarter.
6 Jul, 11:28 — 6 Jul, 11:28
Sources
Showing 1 of 1 sources
